Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze

1. Zuardi AW. History of cannabis as a medicine:a review. Rev Bras Psiquiatr.2006; 28 (2): 153-7.10.1590/S1516-44462006000200015Search in Google Scholar

2. Guy G, Whittle BA, Robson PJ. Medical Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press. 2004.Search in Google Scholar

3. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964; 86: 1646-1647.10.1021/ja01062a046Search in Google Scholar

4. Matsuda LA, Bonner TI and Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol. 1993; 327: 535-550.10.1002/cne.9032704068440779Search in Google Scholar

5. Munro S, Thomas KL and Abu-Sharr M. Molecular characterization of a peripheral receptor for cannabinoids. Nature.1993; 365: 61-65.10.1038/365061a07689702Search in Google Scholar

6. Iversen L.Cannabis and the brain: Review. Brain.2003 Jun; 126 (6): 1252-70.10.1093/brain/awg14312764049Search in Google Scholar

7. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR and Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991; 11: 563-583.10.1523/JNEUROSCI.11-02-00563.1991Search in Google Scholar

8. Hohmann AG, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol. 1999; (81): 575-583.10.1152/jn.1999.81.2.57510036261Search in Google Scholar

9. Sanudo-Pena MC, Strangman NM, Mackie K, Walker JM and Tsou K. CB1 receptor localization in spinal cord and roots, dorsal root ganglion and peripheral nerve. Acta Pharmacol Sin. 1999; (12): 1115-1120.Search in Google Scholar

10. Vaughan VW, Connor M, Bagley EE and Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol. 2000; (57): 288-295.Search in Google Scholar

11. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alchol. 2005; Vol.40 (1): 2-14.10.1093/alcalc/agh11015550444Search in Google Scholar

12. Wegener N, Koch_M. Neurobiology and systems physiology of the endocannabinoid system. Pharmacopsychiatry 2009; 42 (1): 79-8610.1055/s-0029-121634619434559Search in Google Scholar

13. Petrosino S., Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 2010; 11: 51-62.Search in Google Scholar

14. Matthew J. McFarland, Ekaterina A.Terebova and Eric L. Barker. Detergent-Resistant Membrane Microdomains in the Disposition of the Lipid Signaling Molecule Anandamide. 2005 AAPS National Biotechnology Conference Symposium on Lipidomics. 2006: 95-100.10.1208/aapsj080111275142716584138Search in Google Scholar

15. Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG. The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patient undergoing cancer chemotherapy. N Z Med J.1980; (91): 449-451.Search in Google Scholar

16. McCabe M, Smith FP, Goldberg D, Macdonald J, Wooley PV, Warren R. Efficacy of tetrahydrocannabinol in patient refractory to standard antiemetic therapy. Invest New Drugs. 1988; (6): 243-246.10.1007/BF00175407Search in Google Scholar

17. Duran M, Perez E, Abanades S et al. Preliminary efficacy and safety of an oromuscular standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacology. 2010; (70): 656-663.10.1111/j.1365-2125.2010.03743.xSearch in Google Scholar

18. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Sympt Manag.1995; (10): 89-97.10.1016/0885-3924(94)00117-4Search in Google Scholar

19. Strasser F, Luftner D, et al. Canabis in cachexia study group.Comparasion of orally administreted canabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double- blind, placebo-controlled clinical trial from the Cnnabis in cachexia study group. J Clin Oncol. 2006; (24): 3394-3400.10.1200/JCO.2005.05.1847Search in Google Scholar

20. Volicer L,Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patinets with Alzheimer’s disease. Int J Geriatr Psychiatry.1997; (12): 913-919.10.1002/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-DSearch in Google Scholar

21. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain. 2007; (133): 210-220.10.1016/j.pain.2007.08.028Search in Google Scholar

22. Rog DJ, Nurmikko TJ, Friede T, Young CA.Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology.2005; (65): 812-819.10.1212/01.wnl.0000176753.45410.8bSearch in Google Scholar

23. Seeling W,Kneer L, Buchele B, et al. Delta-9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative paip. Anaesthesist. 2006; (55): 391-400.10.1007/s00101-005-0963-6Search in Google Scholar

24. Muller-Vahl KR, Schneider U, Prevedel H, et al. 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome:a 6-week randomized trial. J Clin Psychiatry. 2003; (64): 459-465.10.4088/JCP.v64n0417Search in Google Scholar

25. Sieradzan KA, Fox SH,Dick J, Brotchie JM. The effects of the cannabinoid receptor agonist nabilone on L-dopa induced dyskinesia in patients with idiopathic Parkinon’s disease. Movement disorders.1998; 13 (Suppl 2).Search in Google Scholar

26. Nielsen JB, Crone C., Hultborn H. The spinal pathophysiology of spasticity-from a basic science point of view. Acta Physiologica 2007; 189: 171-180.10.1111/j.1748-1716.2006.01652.xSearch in Google Scholar

27. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL.Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler.2004; 10 (5): 589-595.10.1191/1352458504ms1085oaSearch in Google Scholar

28. Crayton HJ, Rossman HS. Clinical Therapeutics 2006; 28 (4): 445-460.Search in Google Scholar

29. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess_2003; 7(40): 101-111.10.3310/hta7400Search in Google Scholar

30. Bhimani R, Anderson L. Clinical understanding of spasticity: implications for practice. Rehabil Res Pract.2014; 2014:279175. doi: 10.1155/2014/279175.10.1155/2014/279175Search in Google Scholar

31. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med._2000; 160 (22): 415-420.10.1001/archinte.160.22.3415Search in Google Scholar

32. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev.2003; 4:CD001332.10.1002/14651858.CD001332Search in Google Scholar

33. Novotna A, Mares J, Ratcliffe S,et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched- design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011; 2-10.10.1111/j.1468-1331.2010.03328.xSearch in Google Scholar

34. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis.Nerurology.2004; 62:2098-2100.10.1212/01.WNL.0000127707.07621.72Search in Google Scholar

35. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG et al. Endocannabinoids control spasticity in a multiple sclerosis model. Faseb J.2011; 15:300-302.10.1096/fj.00-0399fjeSearch in Google Scholar

36. Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a doublelabel in situ hybridization study. Neuroscience.1999; 90(3): 923-931.10.1016/S0306-4522(98)00524-7Search in Google Scholar

37. Pertwee RG.Cannabinoid receptors and pain. Prog Neurobiology.2010; 63(5): 569-611.10.1016/S0301-0082(00)00031-9Search in Google Scholar

38. Baker D., Pryce G., Jackson SJ., Bolton C., Giovannoni G. The biology that underpins the terapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple sclerosis and Related Disordes 2012; 64: 64-75.10.1016/j.msard.2011.11.00125876933Search in Google Scholar

39. Kmietowicz Z. Cannabis based drug is licensed for spasticity in patients with MS. British Medical Journal 2010; 340: c 3363.10.1136/bmj.c336320570870Search in Google Scholar

40. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg.Med.Chem. 2015; http://dx.doi.org/10.1016/ j.bmc 2015.01.059.Search in Google Scholar

41. Russo E. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011; 163: 1344-1364.10.1111/j.1476-5381.2011.01238.x316594621749363Search in Google Scholar

42. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother. 2006; 7 (5): 607-15.10.1517/14656566.7.5.60716553576Search in Google Scholar

43. Collin C, Ehler E,Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subject with symptoms of spasticity due to multiple sclerosis. Neurol Res.2010; 32(5): 451-459.10.1179/016164109X1259051868566020307378Search in Google Scholar

44. Ashton C John. Emerging treatment options for spasticity in multiple sclerosis-clinical utility of cannabinoids. Degenerative Neurological and Neuromuscular Disease. 2011; 15-23.10.2147/DNND.S16081Search in Google Scholar

45. Tkaczyk M, Florek E, Piekoszewski W. Marihuana and cannabinoids as medicaments. Przegl Lek. 2012; 69 (10): 1095-97.Search in Google Scholar

46. Iversen L. Long-termeffects of exposure to canabis. Curr Opin Pharmacol. 2005;5 (1):69-72 Radhakrishnan R., Wilkinson S. and D Souza DC. Gone to pot-a review of the association between cannabis and psychosis. Frontiers in psychiatry 2014; 54 (5): 1-24.Search in Google Scholar

47. Radhakrishnan R., Wilkinson S. and D Souza DC. Gone to pot-a review of the association between cannabis and psychosis. Frontiers in psychiatry 2014; 54 (5): 1-24.Search in Google Scholar

48. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008; 178 (13): 1669-1678.10.1503/cmaj.071178241330818559804Search in Google Scholar

49. Perez J.Combined cannabinoid therapy via an oromuscular spray. Drugs of Today.2006; 42: 495-503.10.1358/dot.2006.42.8.102151716969427Search in Google Scholar

50. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders. CNS Neurosci Ther. 2009; 15: 65-75.10.1111/j.1755-5949.2008.00065.x649402119228180Search in Google Scholar

51. Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother.2013; 12: 49-54).10.1586/14737175.2013.86587724289844Search in Google Scholar

52. www.mhra.gov.uk. Scheduling of the cannabis-based medicine ‘Sativex’ Accessed in April 2015. Published: 27 March 2013.Search in Google Scholar

53. Barbara S. Koppel, John C.M. Brust, Terry F, Jeff Bronstein,Sarah Youssof, Gary Gronseth and David Gloss. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Neurology. 2014; 82_(17):_1556-1563.10.1212/WNL.0000000000000363401146524778283Search in Google Scholar

54. Wright S.,Yadav V., Bever C Jr et al. Summary of evidence- based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology._2014; 83 (16):1484-1486.10.1212/01.wnl.0000455935.13606.9125313380Search in Google Scholar

55. Potter DJ. A rivew of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal. 2014; 6 (1-2): 31-38.10.1002/dta.153124115748Search in Google Scholar

56. www.zdravlje.gov.rs Zakon o psihoaktivnim kontrolisanim supstancama. Službeni glasnik Republike Srbije br.99/10. Accessed in April 2015.Search in Google Scholar

57. Arroyo R, Vila C, Dechant KL. Impact of Sativex(®) on_quality of life_and activities of daily living in patients with multiple sclerosis spasticity.J Comp Eff Res. 2014; 3(4):435-44. doi: 10.2217/cer.14.30.10.2217/cer.14.3025275238Search in Google Scholar

58. Slof J, Gras A. Sativex in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res. 2012; 12 (4): 439-441 10.1586/erp.12.4022681512Search in Google Scholar